Full Breakdown
New Hormone Treatment Shows Promise for Chronic Back Pain Relief
3/26/2026, 8:23:31 AM
Hormonal Breakthrough in Pain Management
Recent research led by Dr. Janet L. Crane at Johns Hopkins University indicates that parathyroid hormone (PTH), traditionally used to treat osteoporosis, may effectively address chronic back pain by targeting the underlying causes of spinal degeneration. Chronic back pain, often linked to the deterioration of spinal discs and vertebral end plates, affects millions globally and poses significant challenges for effective treatment. The study, published in the journal *Bone Research*, suggests that PTH can prevent and even reverse the abnormal growth of pain-sensing nerves into damaged spinal areas.
Mechanism of Action
The research revealed that PTH stimulates osteoblasts, the bone-building cells, to produce a protein called Slit3. This protein acts as a repellent for nerve fibers, preventing them from infiltrating sensitive regions of the spine. In experiments with mouse models, PTH treatment resulted in denser vertebral end plates and reduced pain sensitivity, indicating a potential shift from merely managing symptoms to modifying the underlying issues causing chronic pain.
Implications for Future Treatments
Dr. Crane emphasized that the findings lay the groundwork for future clinical trials to explore PTH's effectiveness as a disease-modifying and pain-relieving treatment for spinal degeneration. However, researchers acknowledged limitations, including the need to investigate potential effects of PTH on the central nervous system and the influence of other genetic factors on nerve growth and pain relief.
Alternative Approaches to Chronic Back Pain
In parallel, Sunac Therapeutics, a startup from the University of Utah, is developing a genetic therapy aimed at addressing degenerative disc disease (DDD) and chronic back pain. This innovative treatment focuses on cell regeneration and aims to reprogram unhealthy cells to alleviate pain. The therapy involves injecting a specific gene, ZNF865, which is expected to restore normal cell function and significantly reduce pain levels. CEO Steven Laken noted the transformative potential of this approach, which could change the landscape of osteoarthritis research.
Criticism & Opposition
While the studies present promising advancements, some experts urge caution. The reliance on animal models raises questions about the applicability of results to human patients. Additionally, the complexity of chronic back pain, often without a clear structural cause, complicates the translation of these findings into effective treatments.
What's Next
Both the research on PTH and the genetic therapy from Sunac Therapeutics signal a new era in chronic back pain management. Future clinical trials will be essential to validate the efficacy of PTH in humans, while Sunac Therapeutics continues to seek funding to advance its genetic therapy toward commercialization.
Verbatim Quotes
- “During spinal degeneration, pain-sensing nerves grow into regions where they normally do not exist. Our findings show that parathyroid hormone can reverse this process by activating natural signals that push these nerves away,” — Dr. Janet L. Crane, Johns Hopkins University
- “If this works the way that the data shows, this will be a transformative treatment and it would change the trajectory of osteoarthritis research,” — Steven Laken, CEO of Sunac Therapeutics
The ongoing research and development in these areas hold promise for improving the quality of life for those suffering from chronic back pain, potentially offering new avenues for effective treatment.
